Распространенность аутоиммунных эндокринных заболеваний у больных витилиго
Распространенность аутоиммунных эндокринных заболеваний у больных витилиго
Трошина Е.А., Волнухин В.А., Петров В.А. и др. Распространенность аутоиммунных эндокринных заболеваний у больных витилиго. Терапевтический архив. 2020; 92 (10): 88–96. DOI: 10.26442/00403660.2020.10.000736
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Витилиго является распространенным полигенным аутоиммунным заболеванием, при котором в результате гибели меланоцитов образуются очаги депигментации на коже и/или слизистых оболочках. Существует несколько гипотез патогенеза заболевания, среди которых ведущая роль отводится аутоиммунной. В настоящем обзоре обобщены имеющиеся литературные данные, посвященные изучению распространенности и структуры коморбидной эндокринной аутоиммунной патологии у больных витилиго. В большинстве исследований, проведенных в странах Европы, Америки и Азии, у больных витилиго установлена более высокая, по сравнению с общей популяцией, распространенность аутоиммунных заболеваний щитовидной железы (в том числе аутоиммунного тиреоидита и болезни Грейвса), сахарного диабета и аутоиммунной надпочечниковой недостаточности. Результаты отдельных исследований свидетельствуют о частой ассоциации витилиго с аутоиммунными полигландулярными синдромами. В структуре коморбидной патологии наиболее часто встречается ассоциация витилиго с аутоиммунными заболеваниями щитовидной железы. В ряде работ установлена более высокая распространенность аутоиммунных эндокринных заболеваний у женщин, а также у больных несегментарным типом витилиго и в случаях наличия отягощенного семейного анамнеза. Кроме того, показано, что частота развития эндокринных заболеваний возрастает по мере увеличения площади депигментации. Полученные данные обосновывают целесообразность проведения своевременного обследования больных витилиго с целью раннего выявления коморбидных эндокринных заболеваний и назначения соответствующего лечения. Необходимо проведение дальнейших исследований по изучению влияния выявленных ассоциаций на течение витилиго и сопутствующих эндокринопатий, а также эффективность терапии и качество жизни пациентов.
Ключевые слова: витилиго, аутоиммунные заболевания щитовидной железы, аутоиммунный тиреоидит, болезнь Грейвса, сахарный диабет, аутоиммунная надпочечниковая недостаточность, аутоиммунные полигландулярные синдромы.
Keywords: vitiligo, autoimmune thyroid disease, autoimmune thyroiditis, Graves disease, diabetes mellitus, autoimmune adrenal insufficiency, autoimmune polyglandular syndromes.
Ключевые слова: витилиго, аутоиммунные заболевания щитовидной железы, аутоиммунный тиреоидит, болезнь Грейвса, сахарный диабет, аутоиммунная надпочечниковая недостаточность, аутоиммунные полигландулярные синдромы.
________________________________________________
Keywords: vitiligo, autoimmune thyroid disease, autoimmune thyroiditis, Graves disease, diabetes mellitus, autoimmune adrenal insufficiency, autoimmune polyglandular syndromes.
Список литературы
1. Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Health Qual Life Outcomes. 2003 Oct 23;1:58. doi: 10.1186/1477-7525-1-58
2. Krüger C, Schallreuter K. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-12. doi: 10.1111/j.1365-4632.2011.05377.x
3. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7
4. Spritz R, Andersen G. Genetics of vitiligo. Dermatol Clin. 2017;35(2):245-55. doi: 10.1016/j.det.2016.11.013
5. Narita T, Oiso N, Fukai K, et al. Generalized vitiligo associated autoimmune diseases in Japanese patients their families. Allergol Int. 2011;60(4):505-8. doi: 10.2332/allergolint.11-OA-0303
6. Sheth V, Guo Y, Qureshi A. Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology. 2013;227(4):311-5. doi: 10.1159/000354607
7. Gill L, Zarbo A, Isedeh P, et al. Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol. 2016;74(2):295-302. doi: 10.1016/j.jaad.2015.08.063
8. Vrijman C, Kroon M, Limpens J, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol. 2012;167(6):1224-35. doi: 10.1111/j.1365-2133.2012.11198.x
9. Yuan J, Sun C, Jiang S, et al. The prevalence of thyroid disorders in patients with vitiligo: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2019;9:803. doi: 10.3389/fendo.2018.00803
10. Fan KC, Yang TH, Huang YC. Vitiligo and thyroid disease: a systematic review and meta-analysis. Eur J Dermatol.2018;28(6):750-63. doi: 10.1684/ejd.2018.3449
11. Gey A, Diallo A, Seneschal J, et al. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms.
Br J Dermatol. 2013;168(4):756-61. doi: 10.1111/bjd.12166
12. Yazdanpanah MJ, Seyedi Noghabi SA, Taghavi M, et al. Comparison of autoimmune thyroid disease in patients with progressive and stable vitiligo. J Cutan Med Surg. 2016;20(2):135-8. doi: 10.1177/1203475415604551
13. Van Geel N, Speeckaert M, Brochez L, et al. Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. J Eur Acad Dermatol Venereol. 2014;28(6):741-6. doi: 10.1111/jdv.12169
14. Chen Y, Chen Y, Hwang C, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2015;29(7):1362-9. doi: 10.1111/jdv.12870
15. Teulings HE, Ceylan E, Overcamp M, et al. Nonsegmental vitiligo disease duration and female sex are associated with comorbidity and disease extent: a retrospective analysis in 1307 patients aged ≥50 years. Br J Dermatol. 2016;175(4):821. doi: 10.1111/bjd.14640
16. Campi I, Salvi M. Graves’ Disease. In: Huhtaniemi I, Martini L, editors. Encyclopedia of Endocrine Diseases. 2nd ed. Elsevier Inc., 2018; p. 698-701.
17. Iddah M, Macharia B. Autoimmune thyroid disorders. ISRN Endocrinol. 2013;2013:1-9. doi: 10.1155/2013/509764
18. Lazzeri L, Colucci R, Cammi A, et al. Adult onset vitiligo: multivariate analysis suggests the need for a thyroid screening. Biomed Res Int. 2016;2016:1-5. doi: 10.1155/2016/8065765
19. Nicolaidou E, Antoniou C, Miniati A, et al. Childhood- and later-onset vitiligo have diverse epidemiologic and clinical characteristics. J Am Acad Dermatol. 2012;66(6):954-8. doi: 10.1016/j.jaad.2011.07.010
20. Alkhateeb A, Fain P, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in caucasian probands and their families. Pigment Cell Res. 2003;16(3):208-14. doi:10.1034/j.1600-0749.2003.00032.x
21. Laberge G, Mailloux C, Gowan K, et al. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res. 2005;18(4):300-5. doi: 10.1111/j.1600-0749.2005.00242.x
22. Akay BN, Bozkir M, Anadolu Y, Gullu S. Epidemiology of vitiligo, associated autoimmune diseases and audiological abnormalities: Ankara study of 80 patients in Turkey. J Eur Acad Dermatol Venereol. 2010;24(10):1144-50. doi: 10.1111/j.1468-3083.2010.03605.x
23. Birlea SA, Fain PR, Spritz RA. A romanian population isolate with high frequency of vitiligo and associated autoimmune diseases. Arch Dermatol. 2008;144(3):310-6. doi: 10.1001/archderm.144.3.310
24. Cunliffe WJ, Hall R, Newell DJ, Stevenson CJ. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol. 1968;80(3):135-9. doi: 10.1111/j.1365-2133.1968.tb12282.x
25. Hegedüs L, Heidenheim M, Gervil M, et al. High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol. 1994;74(2):120-3. doi: 10.2340/0001555574120123
26. Ingordo V, Cazzaniga S, Raone B, et al. Circulating Aautoantibodies and autoimmune comorbidities in vitiligopatients: a multicenter Italian study. Dermatology. 2014;228(3):240-9. doi: 10.1159/000357807
27. Schallreuter K, Lemke R, Brandt O, et al. Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology. 1994;188(4):269-75. doi: 10.1159/000247164
28. Zettinig G, Tanew A, Fischer G, et al. Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume?. Clin Exp Immunol. 2003;131(2):347-54. doi: 10.1046/j.1365-2249.2003.02089.x
29. Korkij W, Solatani K, Simjee S, et al. Tissue-specific autoantibodies and autoimmune disorders in vitiligo and alopecia areata: a retrospective study. J Cutan Pathol. 1984;11(6):522-30. doi: 10.1111/j.1600-0560.1984.tb00413.x
30. Nunes DH, Esser LM. Vitiligo epidemiological profile and the association with thyroid disease. An Bras Dermatol. 2011;86(2):241-8. doi: 10.1590/s0365-05962011000200006
31. Sawicki J, Siddha S, Rosen C. Vitiligo and associated autoimmune disease: retrospective review of 300 patients. J Cutan Med Surg. 2012;16(4):261-6. doi: 10.1177/120347541201600408
32. Silverberg J, Silverberg N. Clinical features of vitiligo associated with comorbid autoimmune disease: A prospective survey. J Am Acad Dermatol. 2013;69(5):824-6. doi: 10.1016/j.jaad.2013.04.050
33. Al Houssien AO, Al Houssien RO, Al Ajroush W, Al Kahtani HS. Chronic diseases among vitiligo patients. A case control study. Saudi Med J. 2017;38(4):400-4. doi: 10.15537/smj.2017.4.17551
34. Bae J, Lee J, Yun J, et al. Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea. J Am Acad Dermatol. 2017;76(5):871-8. doi: 10.1016/j.jaad.2016.12.034
35. Gopal KV, Rao G, Kumar Y. Increased prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients: A case-control study. Indian Dermatol Online J. 2014;5(4):456. doi: 10.4103/2229-5178.142493
36. Handa S, Kaur I. Vitiligo: clinical findings in 1436 patients. J Dermatol. 1999;26(10):653-57. doi: 10.1111/j.1346-8138.1999.tb02067.x
37. Korde S, Gugle A, Pawar M. A study of association of diabetes mellitus and vitiligo. MVP J Med Sci. 2018;5(2):125-33. doi: 10.18311/mvpjms/2018/v5i2/18265
38. Kumar K, Priya S, Sharma R, et al. Autoimmune thyroid disease in patients with vitiligo: prevalence study in india. Endocr Pract. 2012;18(2):194-9. doi: 10.4158/EP11205.OR
39. Nejad S, Goldust M, Qadim H, et al. Frequency of autoimmune diseases in those suffering from vitiligo in comparison with normal population. Pak J Biol Sci. 2013;16(12):570-4. doi: 10.3923/pjbs.2013.570.574
40. Poojary S. Vitiligo and associated autoimmune disorders: A retrospective hospital-based study in Mumbai, India. Allergol Immunopathol (Madr). 2011;39(6):356-61. doi: 10.1016/j.aller.2010.12.007
41. Saleem K, Azim W. Association of vitiligo with other autoimmune disorders. Diabetes Case Rep. 2016;1(3). doi: 10.4172/2572-5629.1000114
42. Sedighe M, Gholamhossein G. Thyroid dysfunction and thyroid antibodies in Iranian patiens with vitiligo. Indian J Dermatol. 2008;53(1):9-11. doi: 10.4103/0019-5154.39733
43. Sivasubramanian A, Ganapathi S. The study on association of co-morbidities in female patients with vitiligo. Int J Res Dermatol. 2019;5(1):203. doi: 10.18203/issn.2455-4529
44. Tanioka M, Yamamoto Y, Katoh M, et al. Vitiligo vulgaris and autoimmune diseases in Japan: a report from vitiligo clinic in Kyoto University Hospital. Dermatoendocrinol. 2009;1(1):43-5. doi: 10.4161/derm.1.1.7306
45. Topal OI, Duman H, Gungor S, et al. Evaluation of the clinical and sociodemographic features of Turkish patients with vitiligo. Acta Dermatovenerol Croat. 2016;24(2):124-9. https://hrcak.srce.hr/161242
46. Vachiramon V, Harnchoowong S, Onprasert W, Chanprapaph K. Prevalence of thyroid abnormalities in thai patients with vitiligo. Biomed Res Int. 2017;2017:1-6. doi: 10.1155/2017/7502935
47. Yang Y, Huang G, Yan X, Qing Z. Clinical analysis of thyroglobulin antibody and thyroid peroxidase antibody and their association with vitiligo. Indian J Dermatol. 2014;59(4):357. doi: 10.4103/0019-5154.135485
48. Zhang Z, Xu S, Zhang F, et al. The analysis of genetics and associated autoimmune diseases in Chinese vitiligo patients. Arch Dermatol Res. 2009;301(2):167-73. doi: 10.1007/s00403-008-0900-z
49. Iacovelli P, Sinagra J, Vidolin A, et al. Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology. 2005;210(1):26-30. doi: 10.1159/000081479
50. Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, et al. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol. 2005;53(2):220-3. doi: 10.1016/j.jaad.2005.03.032
51. Kroon M, Vrijman C, Chandeck C, et al. High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr.2013;79(3):137-44. doi: 10.1159/000348388
52. Mazereeuw-Hautier J, Bezio S, Mahe E, et al. Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: A prospective observational study. J Am Acad Dermatol. 2010;62(6):945-9. doi: 10.1016/j.jaad.2009.06.081
53. Prćić S, Djuran V, Katanić D, et al. Vitiligo and thyroid dysfunction in children and adolescents. Acta Dermatovenerol Croat. 2011;19(4):248-54.
54. Cho S, Kim J, Cho S, et al. Vitiligo in children and adolescents: association with thyroid dysfunction. J Eur Acad Dermatol Venereol. 2011;25(1):64-7. doi: 10.1111/j.1468-3083.2010.03694.x
55. Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from North India. Pediatr Dermatol. 2003;20(3):207-10. doi: 10.1046/j.1525-1470.2003.20304.x
56. Uncu S, Yaylı S, Bahadır S, et al. Relevance of autoimmune thyroiditis in children and adolescents with vitiligo. Int J Dermatol. 2011;50(2):175-9. doi: 10.1111/j.1365-4632.2010.04665.x
57. Yang Y, Lin X, Fu W, et al. An approach to the correlation between vitiligo and autoimmune thyroiditis in Chinese children. Clin Exp Dermatol. 2010;35(7):706-10. doi: 10.1111/j.1365-2230.2009.03671.x
58. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010 Feb;123(2):183.e1-9. doi: 10.1016/j.amjmed.2009.06.030
59. Ruggeri R, Trimarchi F, Giuffrida G, et al. Autoimmune comorbidities in Hashimoto’s thyroiditis: different patterns of association in adulthood and childhood/adolescence. Eur J Endocrinol. 2017;176(2):133-41. doi: 10.1530/EJE-16-0737
60. Prindaville B, Rivkees S. Incidence of vitiligo in children with Graves' disease and Hashimoto's thyroiditis. Int J Pediatr Endocrinol. 2011;2011(1):18. doi: 10.1186/1687-9856-2011-18
61. Gong Q, Li X, Gong Q, et al. Hashimoto’s thyroiditis could be secondary to vitiligo: the possibility of antigen crossover and oxidative stress between the two diseases. Arch Dermatol Res. 2016;308(4):277-81. doi: 10.1007/s00403-016-1641-z
62. Slominski A, Pisarchik A, Wortsman J, et al. Expression of hypothalamic–pituitary–thyroid axis related genes in the human skin. J Invest Dermatol. 2002;119(6):1449-55. doi: 10.1046/j.1523-1747.2002.19617.x
63. Cianfarani F, Baldini E, Cavalli A, et al. TSH receptor and thyroid-specific gene expression in human skin. J Invest Dermatol. 2010;130(1):93-101. doi: 10.1038/jid.2009.180
64. Ferrari S, Fallahi P, Ruffilli I, et al. The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series. Autoimmun Rev. 2019;18(3):287-92. doi: 10.1016/j.autrev.2018.10.001
65. Liu CW, Huang YC. Vitiligo and autoantibodies: a systematic review and meta-analysis. J Dtsch Dermatol Ges. 2018;16(7):845-51. doi: 10.1111/ddg.13574
66. Lim HK, Bae MI, Jeong KH, et al. Positivity rates of antithyroid antibody, antinuclear antibody and thyroid peroxidase antibody in different types of vitiligo. Clin Exp Dermatol. 2016;41(3):242-7. doi: 10.1111/ced.12771
67. Onunu A, Kubeyinje E. Vitiligo in the Nigerian African: a study of 351 patients in Benin City, Nigeria. Int J Dermatol. 2003;42(10):800-2. doi: 10.1046/j.1365-4362.2003.01908.x
68. Nederstigt C, Uitbeijerse B, Janssen L, et al. Associated autoimmune disease in type 1 diabetes patients: a systematic review and meta-analysis. Eur J Endocrinol. 2019;180(2):135-44. doi: 10.1530/EJE-18-0515
69. Afkhami-Ardekani M, Ghadiri-Anari A, Ebrahimzadeh-Ardakani M, Zaji N. Prevalence of vitiligo among type 2 diabetic patients in an Iranian population. Int J Dermatol. 2014;53(8):956-8. doi: 10.1111/ijd.12148
70. Chang HC, Lin MH, Huang YC, Hou TY. The association between vitiligo and diabetes mellitus: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;81(6):1442-5. doi: 10.1016/j.jaad.2019.06.022
71. Farhan J, Al-Shobaili H, Zafar U, et al. Interleukin-6: a possible inflammatory link between vitiligo and type 1 diabetes. Br J Biomed Sci. 2014;71(4):151-7. doi: 10.1080/09674845.2014.11669980
72. Meyer G, Neumann K, Badenhoop K, Linder R. Increasing prevalence of Addison's disease in German females: health insurance data 2008–2012. Eur J Endocrinol. 2014;170(3):367-73. doi: 10.1530/EJE-13-0756
73. Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome Type 2: the tip of an iceberg? Clin Exp Immunol. 2004;137(2):225-33. doi: 10.1111/j.1365-2249.2004.02561.x
74. Amerio P, Tracanna M, De Remigis P, et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B + C and 4. Clin Exp Dermatol. 2006;31(5):746-9. doi: 10.1111/j.1365-2230.2006.02171.x
75. Amerio P, Di Rollo D, Carbone A, et al. Polyglandular autoimmune diseases in a dermatological clinical setting: vitiligo-associated autoimmune diseases. Eur J Dermatol. 2010;20(3):354-8. doi: 10.1684/ejd.2009.0939
76. Dittmar M, Kahaly G. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab. 2003;88(7):2983-92. doi: 10.1210/jc.2002-021845
77. Perheentupa J. Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. J Clin Endocrinol Metab. 2006;91(8):2843-50. doi: 10.1210/jc.2005-2611
78. Ferre E, Rose S, Rosenzweig S, et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight. 2016;1(13):e88782. doi: 10.1172/jci.insight.88782
79. Bruserud Ø, Oftedal B, Landegren N, et al. A Longitudinal follow-up of Autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2016;101(8):2975-83. doi: 10.1210/jc.2016-1821
80. Туриев Г.С. Аутоиммунные заболевания у больных сахарным диабетом взрослых. Владикавказский медико-биологич. вестн. 2013;17(26):74-80 [Turiev GS. Autoimmune diseases in diabetes mellitus in adult patients. Vladikavkazskij mediko-biologich. vestn. 2013;17(26):74-80 (In Russ.)].
81. Orlova EM, Sozaeva LS, Kareva MA, et al. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2017;102(9):3546-56. doi: 10.1210/jc.2017-00139
82. Ломоносов К.М., Симонова Н.И., Ломоносов М.К. Сравнительный анализ сывороточного содержания аутоантител у больных витилиго. Рос. журн. кожных и венерических болезней. 2013;2:35 [Lomonosov KM, Simonova NI, Lomonosov MK. Comparative analysis of serum autoantibodies in patients with vitiligo. Ros. zhurn. kozhnyh i venericheskih boleznej. 2013;2:35 (In Russ.)].
2. Krüger C, Schallreuter K. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-12. doi: 10.1111/j.1365-4632.2011.05377.x
3. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7
4. Spritz R, Andersen G. Genetics of vitiligo. Dermatol Clin. 2017;35(2):245-55. doi: 10.1016/j.det.2016.11.013
5. Narita T, Oiso N, Fukai K, et al. Generalized vitiligo associated autoimmune diseases in Japanese patients their families. Allergol Int. 2011;60(4):505-8. doi: 10.2332/allergolint.11-OA-0303
6. Sheth V, Guo Y, Qureshi A. Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology. 2013;227(4):311-5. doi: 10.1159/000354607
7. Gill L, Zarbo A, Isedeh P, et al. Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol. 2016;74(2):295-302. doi: 10.1016/j.jaad.2015.08.063
8. Vrijman C, Kroon M, Limpens J, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol. 2012;167(6):1224-35. doi: 10.1111/j.1365-2133.2012.11198.x
9. Yuan J, Sun C, Jiang S, et al. The prevalence of thyroid disorders in patients with vitiligo: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2019;9:803. doi: 10.3389/fendo.2018.00803
10. Fan KC, Yang TH, Huang YC. Vitiligo and thyroid disease: a systematic review and meta-analysis. Eur J Dermatol.2018;28(6):750-63. doi: 10.1684/ejd.2018.3449
11. Gey A, Diallo A, Seneschal J, et al. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms.
Br J Dermatol. 2013;168(4):756-61. doi: 10.1111/bjd.12166
12. Yazdanpanah MJ, Seyedi Noghabi SA, Taghavi M, et al. Comparison of autoimmune thyroid disease in patients with progressive and stable vitiligo. J Cutan Med Surg. 2016;20(2):135-8. doi: 10.1177/1203475415604551
13. Van Geel N, Speeckaert M, Brochez L, et al. Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. J Eur Acad Dermatol Venereol. 2014;28(6):741-6. doi: 10.1111/jdv.12169
14. Chen Y, Chen Y, Hwang C, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2015;29(7):1362-9. doi: 10.1111/jdv.12870
15. Teulings HE, Ceylan E, Overcamp M, et al. Nonsegmental vitiligo disease duration and female sex are associated with comorbidity and disease extent: a retrospective analysis in 1307 patients aged ≥50 years. Br J Dermatol. 2016;175(4):821. doi: 10.1111/bjd.14640
16. Campi I, Salvi M. Graves’ Disease. In: Huhtaniemi I, Martini L, editors. Encyclopedia of Endocrine Diseases. 2nd ed. Elsevier Inc., 2018; p. 698-701.
17. Iddah M, Macharia B. Autoimmune thyroid disorders. ISRN Endocrinol. 2013;2013:1-9. doi: 10.1155/2013/509764
18. Lazzeri L, Colucci R, Cammi A, et al. Adult onset vitiligo: multivariate analysis suggests the need for a thyroid screening. Biomed Res Int. 2016;2016:1-5. doi: 10.1155/2016/8065765
19. Nicolaidou E, Antoniou C, Miniati A, et al. Childhood- and later-onset vitiligo have diverse epidemiologic and clinical characteristics. J Am Acad Dermatol. 2012;66(6):954-8. doi: 10.1016/j.jaad.2011.07.010
20. Alkhateeb A, Fain P, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in caucasian probands and their families. Pigment Cell Res. 2003;16(3):208-14. doi:10.1034/j.1600-0749.2003.00032.x
21. Laberge G, Mailloux C, Gowan K, et al. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res. 2005;18(4):300-5. doi: 10.1111/j.1600-0749.2005.00242.x
22. Akay BN, Bozkir M, Anadolu Y, Gullu S. Epidemiology of vitiligo, associated autoimmune diseases and audiological abnormalities: Ankara study of 80 patients in Turkey. J Eur Acad Dermatol Venereol. 2010;24(10):1144-50. doi: 10.1111/j.1468-3083.2010.03605.x
23. Birlea SA, Fain PR, Spritz RA. A romanian population isolate with high frequency of vitiligo and associated autoimmune diseases. Arch Dermatol. 2008;144(3):310-6. doi: 10.1001/archderm.144.3.310
24. Cunliffe WJ, Hall R, Newell DJ, Stevenson CJ. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol. 1968;80(3):135-9. doi: 10.1111/j.1365-2133.1968.tb12282.x
25. Hegedüs L, Heidenheim M, Gervil M, et al. High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol. 1994;74(2):120-3. doi: 10.2340/0001555574120123
26. Ingordo V, Cazzaniga S, Raone B, et al. Circulating Aautoantibodies and autoimmune comorbidities in vitiligopatients: a multicenter Italian study. Dermatology. 2014;228(3):240-9. doi: 10.1159/000357807
27. Schallreuter K, Lemke R, Brandt O, et al. Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology. 1994;188(4):269-75. doi: 10.1159/000247164
28. Zettinig G, Tanew A, Fischer G, et al. Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume?. Clin Exp Immunol. 2003;131(2):347-54. doi: 10.1046/j.1365-2249.2003.02089.x
29. Korkij W, Solatani K, Simjee S, et al. Tissue-specific autoantibodies and autoimmune disorders in vitiligo and alopecia areata: a retrospective study. J Cutan Pathol. 1984;11(6):522-30. doi: 10.1111/j.1600-0560.1984.tb00413.x
30. Nunes DH, Esser LM. Vitiligo epidemiological profile and the association with thyroid disease. An Bras Dermatol. 2011;86(2):241-8. doi: 10.1590/s0365-05962011000200006
31. Sawicki J, Siddha S, Rosen C. Vitiligo and associated autoimmune disease: retrospective review of 300 patients. J Cutan Med Surg. 2012;16(4):261-6. doi: 10.1177/120347541201600408
32. Silverberg J, Silverberg N. Clinical features of vitiligo associated with comorbid autoimmune disease: A prospective survey. J Am Acad Dermatol. 2013;69(5):824-6. doi: 10.1016/j.jaad.2013.04.050
33. Al Houssien AO, Al Houssien RO, Al Ajroush W, Al Kahtani HS. Chronic diseases among vitiligo patients. A case control study. Saudi Med J. 2017;38(4):400-4. doi: 10.15537/smj.2017.4.17551
34. Bae J, Lee J, Yun J, et al. Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea. J Am Acad Dermatol. 2017;76(5):871-8. doi: 10.1016/j.jaad.2016.12.034
35. Gopal KV, Rao G, Kumar Y. Increased prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients: A case-control study. Indian Dermatol Online J. 2014;5(4):456. doi: 10.4103/2229-5178.142493
36. Handa S, Kaur I. Vitiligo: clinical findings in 1436 patients. J Dermatol. 1999;26(10):653-57. doi: 10.1111/j.1346-8138.1999.tb02067.x
37. Korde S, Gugle A, Pawar M. A study of association of diabetes mellitus and vitiligo. MVP J Med Sci. 2018;5(2):125-33. doi: 10.18311/mvpjms/2018/v5i2/18265
38. Kumar K, Priya S, Sharma R, et al. Autoimmune thyroid disease in patients with vitiligo: prevalence study in india. Endocr Pract. 2012;18(2):194-9. doi: 10.4158/EP11205.OR
39. Nejad S, Goldust M, Qadim H, et al. Frequency of autoimmune diseases in those suffering from vitiligo in comparison with normal population. Pak J Biol Sci. 2013;16(12):570-4. doi: 10.3923/pjbs.2013.570.574
40. Poojary S. Vitiligo and associated autoimmune disorders: A retrospective hospital-based study in Mumbai, India. Allergol Immunopathol (Madr). 2011;39(6):356-61. doi: 10.1016/j.aller.2010.12.007
41. Saleem K, Azim W. Association of vitiligo with other autoimmune disorders. Diabetes Case Rep. 2016;1(3). doi: 10.4172/2572-5629.1000114
42. Sedighe M, Gholamhossein G. Thyroid dysfunction and thyroid antibodies in Iranian patiens with vitiligo. Indian J Dermatol. 2008;53(1):9-11. doi: 10.4103/0019-5154.39733
43. Sivasubramanian A, Ganapathi S. The study on association of co-morbidities in female patients with vitiligo. Int J Res Dermatol. 2019;5(1):203. doi: 10.18203/issn.2455-4529
44. Tanioka M, Yamamoto Y, Katoh M, et al. Vitiligo vulgaris and autoimmune diseases in Japan: a report from vitiligo clinic in Kyoto University Hospital. Dermatoendocrinol. 2009;1(1):43-5. doi: 10.4161/derm.1.1.7306
45. Topal OI, Duman H, Gungor S, et al. Evaluation of the clinical and sociodemographic features of Turkish patients with vitiligo. Acta Dermatovenerol Croat. 2016;24(2):124-9. https://hrcak.srce.hr/161242
46. Vachiramon V, Harnchoowong S, Onprasert W, Chanprapaph K. Prevalence of thyroid abnormalities in thai patients with vitiligo. Biomed Res Int. 2017;2017:1-6. doi: 10.1155/2017/7502935
47. Yang Y, Huang G, Yan X, Qing Z. Clinical analysis of thyroglobulin antibody and thyroid peroxidase antibody and their association with vitiligo. Indian J Dermatol. 2014;59(4):357. doi: 10.4103/0019-5154.135485
48. Zhang Z, Xu S, Zhang F, et al. The analysis of genetics and associated autoimmune diseases in Chinese vitiligo patients. Arch Dermatol Res. 2009;301(2):167-73. doi: 10.1007/s00403-008-0900-z
49. Iacovelli P, Sinagra J, Vidolin A, et al. Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology. 2005;210(1):26-30. doi: 10.1159/000081479
50. Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, et al. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol. 2005;53(2):220-3. doi: 10.1016/j.jaad.2005.03.032
51. Kroon M, Vrijman C, Chandeck C, et al. High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr.2013;79(3):137-44. doi: 10.1159/000348388
52. Mazereeuw-Hautier J, Bezio S, Mahe E, et al. Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: A prospective observational study. J Am Acad Dermatol. 2010;62(6):945-9. doi: 10.1016/j.jaad.2009.06.081
53. Prćić S, Djuran V, Katanić D, et al. Vitiligo and thyroid dysfunction in children and adolescents. Acta Dermatovenerol Croat. 2011;19(4):248-54.
54. Cho S, Kim J, Cho S, et al. Vitiligo in children and adolescents: association with thyroid dysfunction. J Eur Acad Dermatol Venereol. 2011;25(1):64-7. doi: 10.1111/j.1468-3083.2010.03694.x
55. Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from North India. Pediatr Dermatol. 2003;20(3):207-10. doi: 10.1046/j.1525-1470.2003.20304.x
56. Uncu S, Yaylı S, Bahadır S, et al. Relevance of autoimmune thyroiditis in children and adolescents with vitiligo. Int J Dermatol. 2011;50(2):175-9. doi: 10.1111/j.1365-4632.2010.04665.x
57. Yang Y, Lin X, Fu W, et al. An approach to the correlation between vitiligo and autoimmune thyroiditis in Chinese children. Clin Exp Dermatol. 2010;35(7):706-10. doi: 10.1111/j.1365-2230.2009.03671.x
58. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010 Feb;123(2):183.e1-9. doi: 10.1016/j.amjmed.2009.06.030
59. Ruggeri R, Trimarchi F, Giuffrida G, et al. Autoimmune comorbidities in Hashimoto’s thyroiditis: different patterns of association in adulthood and childhood/adolescence. Eur J Endocrinol. 2017;176(2):133-41. doi: 10.1530/EJE-16-0737
60. Prindaville B, Rivkees S. Incidence of vitiligo in children with Graves' disease and Hashimoto's thyroiditis. Int J Pediatr Endocrinol. 2011;2011(1):18. doi: 10.1186/1687-9856-2011-18
61. Gong Q, Li X, Gong Q, et al. Hashimoto’s thyroiditis could be secondary to vitiligo: the possibility of antigen crossover and oxidative stress between the two diseases. Arch Dermatol Res. 2016;308(4):277-81. doi: 10.1007/s00403-016-1641-z
62. Slominski A, Pisarchik A, Wortsman J, et al. Expression of hypothalamic–pituitary–thyroid axis related genes in the human skin. J Invest Dermatol. 2002;119(6):1449-55. doi: 10.1046/j.1523-1747.2002.19617.x
63. Cianfarani F, Baldini E, Cavalli A, et al. TSH receptor and thyroid-specific gene expression in human skin. J Invest Dermatol. 2010;130(1):93-101. doi: 10.1038/jid.2009.180
64. Ferrari S, Fallahi P, Ruffilli I, et al. The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series. Autoimmun Rev. 2019;18(3):287-92. doi: 10.1016/j.autrev.2018.10.001
65. Liu CW, Huang YC. Vitiligo and autoantibodies: a systematic review and meta-analysis. J Dtsch Dermatol Ges. 2018;16(7):845-51. doi: 10.1111/ddg.13574
66. Lim HK, Bae MI, Jeong KH, et al. Positivity rates of antithyroid antibody, antinuclear antibody and thyroid peroxidase antibody in different types of vitiligo. Clin Exp Dermatol. 2016;41(3):242-7. doi: 10.1111/ced.12771
67. Onunu A, Kubeyinje E. Vitiligo in the Nigerian African: a study of 351 patients in Benin City, Nigeria. Int J Dermatol. 2003;42(10):800-2. doi: 10.1046/j.1365-4362.2003.01908.x
68. Nederstigt C, Uitbeijerse B, Janssen L, et al. Associated autoimmune disease in type 1 diabetes patients: a systematic review and meta-analysis. Eur J Endocrinol. 2019;180(2):135-44. doi: 10.1530/EJE-18-0515
69. Afkhami-Ardekani M, Ghadiri-Anari A, Ebrahimzadeh-Ardakani M, Zaji N. Prevalence of vitiligo among type 2 diabetic patients in an Iranian population. Int J Dermatol. 2014;53(8):956-8. doi: 10.1111/ijd.12148
70. Chang HC, Lin MH, Huang YC, Hou TY. The association between vitiligo and diabetes mellitus: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;81(6):1442-5. doi: 10.1016/j.jaad.2019.06.022
71. Farhan J, Al-Shobaili H, Zafar U, et al. Interleukin-6: a possible inflammatory link between vitiligo and type 1 diabetes. Br J Biomed Sci. 2014;71(4):151-7. doi: 10.1080/09674845.2014.11669980
72. Meyer G, Neumann K, Badenhoop K, Linder R. Increasing prevalence of Addison's disease in German females: health insurance data 2008–2012. Eur J Endocrinol. 2014;170(3):367-73. doi: 10.1530/EJE-13-0756
73. Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome Type 2: the tip of an iceberg? Clin Exp Immunol. 2004;137(2):225-33. doi: 10.1111/j.1365-2249.2004.02561.x
74. Amerio P, Tracanna M, De Remigis P, et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B + C and 4. Clin Exp Dermatol. 2006;31(5):746-9. doi: 10.1111/j.1365-2230.2006.02171.x
75. Amerio P, Di Rollo D, Carbone A, et al. Polyglandular autoimmune diseases in a dermatological clinical setting: vitiligo-associated autoimmune diseases. Eur J Dermatol. 2010;20(3):354-8. doi: 10.1684/ejd.2009.0939
76. Dittmar M, Kahaly G. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab. 2003;88(7):2983-92. doi: 10.1210/jc.2002-021845
77. Perheentupa J. Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. J Clin Endocrinol Metab. 2006;91(8):2843-50. doi: 10.1210/jc.2005-2611
78. Ferre E, Rose S, Rosenzweig S, et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight. 2016;1(13):e88782. doi: 10.1172/jci.insight.88782
79. Bruserud Ø, Oftedal B, Landegren N, et al. A Longitudinal follow-up of Autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2016;101(8):2975-83. doi: 10.1210/jc.2016-1821
80. Turiev GS. Autoimmune diseases in diabetes mellitus in adult patients. Vladikavkazskij mediko-biologich. vestn. 2013;17(26):74-80 (In Russ.)
81. Orlova EM, Sozaeva LS, Kareva MA, et al. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2017;102(9):3546-56. doi: 10.1210/jc.2017-00139
82. Lomonosov KM, Simonova NI, Lomonosov MK. Comparative analysis of serum autoantibodies in patients with vitiligo. Ros. zhurn. kozhnyh i venericheskih boleznej. 2013;2:35 (In Russ.)
2. Krüger C, Schallreuter K. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-12. doi: 10.1111/j.1365-4632.2011.05377.x
3. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7
4. Spritz R, Andersen G. Genetics of vitiligo. Dermatol Clin. 2017;35(2):245-55. doi: 10.1016/j.det.2016.11.013
5. Narita T, Oiso N, Fukai K, et al. Generalized vitiligo associated autoimmune diseases in Japanese patients their families. Allergol Int. 2011;60(4):505-8. doi: 10.2332/allergolint.11-OA-0303
6. Sheth V, Guo Y, Qureshi A. Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology. 2013;227(4):311-5. doi: 10.1159/000354607
7. Gill L, Zarbo A, Isedeh P, et al. Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol. 2016;74(2):295-302. doi: 10.1016/j.jaad.2015.08.063
8. Vrijman C, Kroon M, Limpens J, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol. 2012;167(6):1224-35. doi: 10.1111/j.1365-2133.2012.11198.x
9. Yuan J, Sun C, Jiang S, et al. The prevalence of thyroid disorders in patients with vitiligo: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2019;9:803. doi: 10.3389/fendo.2018.00803
10. Fan KC, Yang TH, Huang YC. Vitiligo and thyroid disease: a systematic review and meta-analysis. Eur J Dermatol.2018;28(6):750-63. doi: 10.1684/ejd.2018.3449
11. Gey A, Diallo A, Seneschal J, et al. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms.
Br J Dermatol. 2013;168(4):756-61. doi: 10.1111/bjd.12166
12. Yazdanpanah MJ, Seyedi Noghabi SA, Taghavi M, et al. Comparison of autoimmune thyroid disease in patients with progressive and stable vitiligo. J Cutan Med Surg. 2016;20(2):135-8. doi: 10.1177/1203475415604551
13. Van Geel N, Speeckaert M, Brochez L, et al. Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. J Eur Acad Dermatol Venereol. 2014;28(6):741-6. doi: 10.1111/jdv.12169
14. Chen Y, Chen Y, Hwang C, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2015;29(7):1362-9. doi: 10.1111/jdv.12870
15. Teulings HE, Ceylan E, Overcamp M, et al. Nonsegmental vitiligo disease duration and female sex are associated with comorbidity and disease extent: a retrospective analysis in 1307 patients aged ≥50 years. Br J Dermatol. 2016;175(4):821. doi: 10.1111/bjd.14640
16. Campi I, Salvi M. Graves’ Disease. In: Huhtaniemi I, Martini L, editors. Encyclopedia of Endocrine Diseases. 2nd ed. Elsevier Inc., 2018; p. 698-701.
17. Iddah M, Macharia B. Autoimmune thyroid disorders. ISRN Endocrinol. 2013;2013:1-9. doi: 10.1155/2013/509764
18. Lazzeri L, Colucci R, Cammi A, et al. Adult onset vitiligo: multivariate analysis suggests the need for a thyroid screening. Biomed Res Int. 2016;2016:1-5. doi: 10.1155/2016/8065765
19. Nicolaidou E, Antoniou C, Miniati A, et al. Childhood- and later-onset vitiligo have diverse epidemiologic and clinical characteristics. J Am Acad Dermatol. 2012;66(6):954-8. doi: 10.1016/j.jaad.2011.07.010
20. Alkhateeb A, Fain P, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in caucasian probands and their families. Pigment Cell Res. 2003;16(3):208-14. doi:10.1034/j.1600-0749.2003.00032.x
21. Laberge G, Mailloux C, Gowan K, et al. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res. 2005;18(4):300-5. doi: 10.1111/j.1600-0749.2005.00242.x
22. Akay BN, Bozkir M, Anadolu Y, Gullu S. Epidemiology of vitiligo, associated autoimmune diseases and audiological abnormalities: Ankara study of 80 patients in Turkey. J Eur Acad Dermatol Venereol. 2010;24(10):1144-50. doi: 10.1111/j.1468-3083.2010.03605.x
23. Birlea SA, Fain PR, Spritz RA. A romanian population isolate with high frequency of vitiligo and associated autoimmune diseases. Arch Dermatol. 2008;144(3):310-6. doi: 10.1001/archderm.144.3.310
24. Cunliffe WJ, Hall R, Newell DJ, Stevenson CJ. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol. 1968;80(3):135-9. doi: 10.1111/j.1365-2133.1968.tb12282.x
25. Hegedüs L, Heidenheim M, Gervil M, et al. High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol. 1994;74(2):120-3. doi: 10.2340/0001555574120123
26. Ingordo V, Cazzaniga S, Raone B, et al. Circulating Aautoantibodies and autoimmune comorbidities in vitiligopatients: a multicenter Italian study. Dermatology. 2014;228(3):240-9. doi: 10.1159/000357807
27. Schallreuter K, Lemke R, Brandt O, et al. Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology. 1994;188(4):269-75. doi: 10.1159/000247164
28. Zettinig G, Tanew A, Fischer G, et al. Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume?. Clin Exp Immunol. 2003;131(2):347-54. doi: 10.1046/j.1365-2249.2003.02089.x
29. Korkij W, Solatani K, Simjee S, et al. Tissue-specific autoantibodies and autoimmune disorders in vitiligo and alopecia areata: a retrospective study. J Cutan Pathol. 1984;11(6):522-30. doi: 10.1111/j.1600-0560.1984.tb00413.x
30. Nunes DH, Esser LM. Vitiligo epidemiological profile and the association with thyroid disease. An Bras Dermatol. 2011;86(2):241-8. doi: 10.1590/s0365-05962011000200006
31. Sawicki J, Siddha S, Rosen C. Vitiligo and associated autoimmune disease: retrospective review of 300 patients. J Cutan Med Surg. 2012;16(4):261-6. doi: 10.1177/120347541201600408
32. Silverberg J, Silverberg N. Clinical features of vitiligo associated with comorbid autoimmune disease: A prospective survey. J Am Acad Dermatol. 2013;69(5):824-6. doi: 10.1016/j.jaad.2013.04.050
33. Al Houssien AO, Al Houssien RO, Al Ajroush W, Al Kahtani HS. Chronic diseases among vitiligo patients. A case control study. Saudi Med J. 2017;38(4):400-4. doi: 10.15537/smj.2017.4.17551
34. Bae J, Lee J, Yun J, et al. Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea. J Am Acad Dermatol. 2017;76(5):871-8. doi: 10.1016/j.jaad.2016.12.034
35. Gopal KV, Rao G, Kumar Y. Increased prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients: A case-control study. Indian Dermatol Online J. 2014;5(4):456. doi: 10.4103/2229-5178.142493
36. Handa S, Kaur I. Vitiligo: clinical findings in 1436 patients. J Dermatol. 1999;26(10):653-57. doi: 10.1111/j.1346-8138.1999.tb02067.x
37. Korde S, Gugle A, Pawar M. A study of association of diabetes mellitus and vitiligo. MVP J Med Sci. 2018;5(2):125-33. doi: 10.18311/mvpjms/2018/v5i2/18265
38. Kumar K, Priya S, Sharma R, et al. Autoimmune thyroid disease in patients with vitiligo: prevalence study in india. Endocr Pract. 2012;18(2):194-9. doi: 10.4158/EP11205.OR
39. Nejad S, Goldust M, Qadim H, et al. Frequency of autoimmune diseases in those suffering from vitiligo in comparison with normal population. Pak J Biol Sci. 2013;16(12):570-4. doi: 10.3923/pjbs.2013.570.574
40. Poojary S. Vitiligo and associated autoimmune disorders: A retrospective hospital-based study in Mumbai, India. Allergol Immunopathol (Madr). 2011;39(6):356-61. doi: 10.1016/j.aller.2010.12.007
41. Saleem K, Azim W. Association of vitiligo with other autoimmune disorders. Diabetes Case Rep. 2016;1(3). doi: 10.4172/2572-5629.1000114
42. Sedighe M, Gholamhossein G. Thyroid dysfunction and thyroid antibodies in Iranian patiens with vitiligo. Indian J Dermatol. 2008;53(1):9-11. doi: 10.4103/0019-5154.39733
43. Sivasubramanian A, Ganapathi S. The study on association of co-morbidities in female patients with vitiligo. Int J Res Dermatol. 2019;5(1):203. doi: 10.18203/issn.2455-4529
44. Tanioka M, Yamamoto Y, Katoh M, et al. Vitiligo vulgaris and autoimmune diseases in Japan: a report from vitiligo clinic in Kyoto University Hospital. Dermatoendocrinol. 2009;1(1):43-5. doi: 10.4161/derm.1.1.7306
45. Topal OI, Duman H, Gungor S, et al. Evaluation of the clinical and sociodemographic features of Turkish patients with vitiligo. Acta Dermatovenerol Croat. 2016;24(2):124-9. https://hrcak.srce.hr/161242
46. Vachiramon V, Harnchoowong S, Onprasert W, Chanprapaph K. Prevalence of thyroid abnormalities in thai patients with vitiligo. Biomed Res Int. 2017;2017:1-6. doi: 10.1155/2017/7502935
47. Yang Y, Huang G, Yan X, Qing Z. Clinical analysis of thyroglobulin antibody and thyroid peroxidase antibody and their association with vitiligo. Indian J Dermatol. 2014;59(4):357. doi: 10.4103/0019-5154.135485
48. Zhang Z, Xu S, Zhang F, et al. The analysis of genetics and associated autoimmune diseases in Chinese vitiligo patients. Arch Dermatol Res. 2009;301(2):167-73. doi: 10.1007/s00403-008-0900-z
49. Iacovelli P, Sinagra J, Vidolin A, et al. Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology. 2005;210(1):26-30. doi: 10.1159/000081479
50. Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, et al. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol. 2005;53(2):220-3. doi: 10.1016/j.jaad.2005.03.032
51. Kroon M, Vrijman C, Chandeck C, et al. High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr.2013;79(3):137-44. doi: 10.1159/000348388
52. Mazereeuw-Hautier J, Bezio S, Mahe E, et al. Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: A prospective observational study. J Am Acad Dermatol. 2010;62(6):945-9. doi: 10.1016/j.jaad.2009.06.081
53. Prćić S, Djuran V, Katanić D, et al. Vitiligo and thyroid dysfunction in children and adolescents. Acta Dermatovenerol Croat. 2011;19(4):248-54.
54. Cho S, Kim J, Cho S, et al. Vitiligo in children and adolescents: association with thyroid dysfunction. J Eur Acad Dermatol Venereol. 2011;25(1):64-7. doi: 10.1111/j.1468-3083.2010.03694.x
55. Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from North India. Pediatr Dermatol. 2003;20(3):207-10. doi: 10.1046/j.1525-1470.2003.20304.x
56. Uncu S, Yaylı S, Bahadır S, et al. Relevance of autoimmune thyroiditis in children and adolescents with vitiligo. Int J Dermatol. 2011;50(2):175-9. doi: 10.1111/j.1365-4632.2010.04665.x
57. Yang Y, Lin X, Fu W, et al. An approach to the correlation between vitiligo and autoimmune thyroiditis in Chinese children. Clin Exp Dermatol. 2010;35(7):706-10. doi: 10.1111/j.1365-2230.2009.03671.x
58. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010 Feb;123(2):183.e1-9. doi: 10.1016/j.amjmed.2009.06.030
59. Ruggeri R, Trimarchi F, Giuffrida G, et al. Autoimmune comorbidities in Hashimoto’s thyroiditis: different patterns of association in adulthood and childhood/adolescence. Eur J Endocrinol. 2017;176(2):133-41. doi: 10.1530/EJE-16-0737
60. Prindaville B, Rivkees S. Incidence of vitiligo in children with Graves' disease and Hashimoto's thyroiditis. Int J Pediatr Endocrinol. 2011;2011(1):18. doi: 10.1186/1687-9856-2011-18
61. Gong Q, Li X, Gong Q, et al. Hashimoto’s thyroiditis could be secondary to vitiligo: the possibility of antigen crossover and oxidative stress between the two diseases. Arch Dermatol Res. 2016;308(4):277-81. doi: 10.1007/s00403-016-1641-z
62. Slominski A, Pisarchik A, Wortsman J, et al. Expression of hypothalamic–pituitary–thyroid axis related genes in the human skin. J Invest Dermatol. 2002;119(6):1449-55. doi: 10.1046/j.1523-1747.2002.19617.x
63. Cianfarani F, Baldini E, Cavalli A, et al. TSH receptor and thyroid-specific gene expression in human skin. J Invest Dermatol. 2010;130(1):93-101. doi: 10.1038/jid.2009.180
64. Ferrari S, Fallahi P, Ruffilli I, et al. The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series. Autoimmun Rev. 2019;18(3):287-92. doi: 10.1016/j.autrev.2018.10.001
65. Liu CW, Huang YC. Vitiligo and autoantibodies: a systematic review and meta-analysis. J Dtsch Dermatol Ges. 2018;16(7):845-51. doi: 10.1111/ddg.13574
66. Lim HK, Bae MI, Jeong KH, et al. Positivity rates of antithyroid antibody, antinuclear antibody and thyroid peroxidase antibody in different types of vitiligo. Clin Exp Dermatol. 2016;41(3):242-7. doi: 10.1111/ced.12771
67. Onunu A, Kubeyinje E. Vitiligo in the Nigerian African: a study of 351 patients in Benin City, Nigeria. Int J Dermatol. 2003;42(10):800-2. doi: 10.1046/j.1365-4362.2003.01908.x
68. Nederstigt C, Uitbeijerse B, Janssen L, et al. Associated autoimmune disease in type 1 diabetes patients: a systematic review and meta-analysis. Eur J Endocrinol. 2019;180(2):135-44. doi: 10.1530/EJE-18-0515
69. Afkhami-Ardekani M, Ghadiri-Anari A, Ebrahimzadeh-Ardakani M, Zaji N. Prevalence of vitiligo among type 2 diabetic patients in an Iranian population. Int J Dermatol. 2014;53(8):956-8. doi: 10.1111/ijd.12148
70. Chang HC, Lin MH, Huang YC, Hou TY. The association between vitiligo and diabetes mellitus: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;81(6):1442-5. doi: 10.1016/j.jaad.2019.06.022
71. Farhan J, Al-Shobaili H, Zafar U, et al. Interleukin-6: a possible inflammatory link between vitiligo and type 1 diabetes. Br J Biomed Sci. 2014;71(4):151-7. doi: 10.1080/09674845.2014.11669980
72. Meyer G, Neumann K, Badenhoop K, Linder R. Increasing prevalence of Addison's disease in German females: health insurance data 2008–2012. Eur J Endocrinol. 2014;170(3):367-73. doi: 10.1530/EJE-13-0756
73. Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome Type 2: the tip of an iceberg? Clin Exp Immunol. 2004;137(2):225-33. doi: 10.1111/j.1365-2249.2004.02561.x
74. Amerio P, Tracanna M, De Remigis P, et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B + C and 4. Clin Exp Dermatol. 2006;31(5):746-9. doi: 10.1111/j.1365-2230.2006.02171.x
75. Amerio P, Di Rollo D, Carbone A, et al. Polyglandular autoimmune diseases in a dermatological clinical setting: vitiligo-associated autoimmune diseases. Eur J Dermatol. 2010;20(3):354-8. doi: 10.1684/ejd.2009.0939
76. Dittmar M, Kahaly G. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab. 2003;88(7):2983-92. doi: 10.1210/jc.2002-021845
77. Perheentupa J. Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. J Clin Endocrinol Metab. 2006;91(8):2843-50. doi: 10.1210/jc.2005-2611
78. Ferre E, Rose S, Rosenzweig S, et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight. 2016;1(13):e88782. doi: 10.1172/jci.insight.88782
79. Bruserud Ø, Oftedal B, Landegren N, et al. A Longitudinal follow-up of Autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2016;101(8):2975-83. doi: 10.1210/jc.2016-1821
80. Туриев Г.С. Аутоиммунные заболевания у больных сахарным диабетом взрослых. Владикавказский медико-биологич. вестн. 2013;17(26):74-80 [Turiev GS. Autoimmune diseases in diabetes mellitus in adult patients. Vladikavkazskij mediko-biologich. vestn. 2013;17(26):74-80 (In Russ.)].
81. Orlova EM, Sozaeva LS, Kareva MA, et al. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2017;102(9):3546-56. doi: 10.1210/jc.2017-00139
82. Ломоносов К.М., Симонова Н.И., Ломоносов М.К. Сравнительный анализ сывороточного содержания аутоантител у больных витилиго. Рос. журн. кожных и венерических болезней. 2013;2:35 [Lomonosov KM, Simonova NI, Lomonosov MK. Comparative analysis of serum autoantibodies in patients with vitiligo. Ros. zhurn. kozhnyh i venericheskih boleznej. 2013;2:35 (In Russ.)].
________________________________________________
2. Krüger C, Schallreuter K. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-12. doi: 10.1111/j.1365-4632.2011.05377.x
3. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7
4. Spritz R, Andersen G. Genetics of vitiligo. Dermatol Clin. 2017;35(2):245-55. doi: 10.1016/j.det.2016.11.013
5. Narita T, Oiso N, Fukai K, et al. Generalized vitiligo associated autoimmune diseases in Japanese patients their families. Allergol Int. 2011;60(4):505-8. doi: 10.2332/allergolint.11-OA-0303
6. Sheth V, Guo Y, Qureshi A. Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology. 2013;227(4):311-5. doi: 10.1159/000354607
7. Gill L, Zarbo A, Isedeh P, et al. Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol. 2016;74(2):295-302. doi: 10.1016/j.jaad.2015.08.063
8. Vrijman C, Kroon M, Limpens J, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol. 2012;167(6):1224-35. doi: 10.1111/j.1365-2133.2012.11198.x
9. Yuan J, Sun C, Jiang S, et al. The prevalence of thyroid disorders in patients with vitiligo: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2019;9:803. doi: 10.3389/fendo.2018.00803
10. Fan KC, Yang TH, Huang YC. Vitiligo and thyroid disease: a systematic review and meta-analysis. Eur J Dermatol.2018;28(6):750-63. doi: 10.1684/ejd.2018.3449
11. Gey A, Diallo A, Seneschal J, et al. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms.
Br J Dermatol. 2013;168(4):756-61. doi: 10.1111/bjd.12166
12. Yazdanpanah MJ, Seyedi Noghabi SA, Taghavi M, et al. Comparison of autoimmune thyroid disease in patients with progressive and stable vitiligo. J Cutan Med Surg. 2016;20(2):135-8. doi: 10.1177/1203475415604551
13. Van Geel N, Speeckaert M, Brochez L, et al. Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. J Eur Acad Dermatol Venereol. 2014;28(6):741-6. doi: 10.1111/jdv.12169
14. Chen Y, Chen Y, Hwang C, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2015;29(7):1362-9. doi: 10.1111/jdv.12870
15. Teulings HE, Ceylan E, Overcamp M, et al. Nonsegmental vitiligo disease duration and female sex are associated with comorbidity and disease extent: a retrospective analysis in 1307 patients aged ≥50 years. Br J Dermatol. 2016;175(4):821. doi: 10.1111/bjd.14640
16. Campi I, Salvi M. Graves’ Disease. In: Huhtaniemi I, Martini L, editors. Encyclopedia of Endocrine Diseases. 2nd ed. Elsevier Inc., 2018; p. 698-701.
17. Iddah M, Macharia B. Autoimmune thyroid disorders. ISRN Endocrinol. 2013;2013:1-9. doi: 10.1155/2013/509764
18. Lazzeri L, Colucci R, Cammi A, et al. Adult onset vitiligo: multivariate analysis suggests the need for a thyroid screening. Biomed Res Int. 2016;2016:1-5. doi: 10.1155/2016/8065765
19. Nicolaidou E, Antoniou C, Miniati A, et al. Childhood- and later-onset vitiligo have diverse epidemiologic and clinical characteristics. J Am Acad Dermatol. 2012;66(6):954-8. doi: 10.1016/j.jaad.2011.07.010
20. Alkhateeb A, Fain P, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in caucasian probands and their families. Pigment Cell Res. 2003;16(3):208-14. doi:10.1034/j.1600-0749.2003.00032.x
21. Laberge G, Mailloux C, Gowan K, et al. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res. 2005;18(4):300-5. doi: 10.1111/j.1600-0749.2005.00242.x
22. Akay BN, Bozkir M, Anadolu Y, Gullu S. Epidemiology of vitiligo, associated autoimmune diseases and audiological abnormalities: Ankara study of 80 patients in Turkey. J Eur Acad Dermatol Venereol. 2010;24(10):1144-50. doi: 10.1111/j.1468-3083.2010.03605.x
23. Birlea SA, Fain PR, Spritz RA. A romanian population isolate with high frequency of vitiligo and associated autoimmune diseases. Arch Dermatol. 2008;144(3):310-6. doi: 10.1001/archderm.144.3.310
24. Cunliffe WJ, Hall R, Newell DJ, Stevenson CJ. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol. 1968;80(3):135-9. doi: 10.1111/j.1365-2133.1968.tb12282.x
25. Hegedüs L, Heidenheim M, Gervil M, et al. High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol. 1994;74(2):120-3. doi: 10.2340/0001555574120123
26. Ingordo V, Cazzaniga S, Raone B, et al. Circulating Aautoantibodies and autoimmune comorbidities in vitiligopatients: a multicenter Italian study. Dermatology. 2014;228(3):240-9. doi: 10.1159/000357807
27. Schallreuter K, Lemke R, Brandt O, et al. Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology. 1994;188(4):269-75. doi: 10.1159/000247164
28. Zettinig G, Tanew A, Fischer G, et al. Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume?. Clin Exp Immunol. 2003;131(2):347-54. doi: 10.1046/j.1365-2249.2003.02089.x
29. Korkij W, Solatani K, Simjee S, et al. Tissue-specific autoantibodies and autoimmune disorders in vitiligo and alopecia areata: a retrospective study. J Cutan Pathol. 1984;11(6):522-30. doi: 10.1111/j.1600-0560.1984.tb00413.x
30. Nunes DH, Esser LM. Vitiligo epidemiological profile and the association with thyroid disease. An Bras Dermatol. 2011;86(2):241-8. doi: 10.1590/s0365-05962011000200006
31. Sawicki J, Siddha S, Rosen C. Vitiligo and associated autoimmune disease: retrospective review of 300 patients. J Cutan Med Surg. 2012;16(4):261-6. doi: 10.1177/120347541201600408
32. Silverberg J, Silverberg N. Clinical features of vitiligo associated with comorbid autoimmune disease: A prospective survey. J Am Acad Dermatol. 2013;69(5):824-6. doi: 10.1016/j.jaad.2013.04.050
33. Al Houssien AO, Al Houssien RO, Al Ajroush W, Al Kahtani HS. Chronic diseases among vitiligo patients. A case control study. Saudi Med J. 2017;38(4):400-4. doi: 10.15537/smj.2017.4.17551
34. Bae J, Lee J, Yun J, et al. Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea. J Am Acad Dermatol. 2017;76(5):871-8. doi: 10.1016/j.jaad.2016.12.034
35. Gopal KV, Rao G, Kumar Y. Increased prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients: A case-control study. Indian Dermatol Online J. 2014;5(4):456. doi: 10.4103/2229-5178.142493
36. Handa S, Kaur I. Vitiligo: clinical findings in 1436 patients. J Dermatol. 1999;26(10):653-57. doi: 10.1111/j.1346-8138.1999.tb02067.x
37. Korde S, Gugle A, Pawar M. A study of association of diabetes mellitus and vitiligo. MVP J Med Sci. 2018;5(2):125-33. doi: 10.18311/mvpjms/2018/v5i2/18265
38. Kumar K, Priya S, Sharma R, et al. Autoimmune thyroid disease in patients with vitiligo: prevalence study in india. Endocr Pract. 2012;18(2):194-9. doi: 10.4158/EP11205.OR
39. Nejad S, Goldust M, Qadim H, et al. Frequency of autoimmune diseases in those suffering from vitiligo in comparison with normal population. Pak J Biol Sci. 2013;16(12):570-4. doi: 10.3923/pjbs.2013.570.574
40. Poojary S. Vitiligo and associated autoimmune disorders: A retrospective hospital-based study in Mumbai, India. Allergol Immunopathol (Madr). 2011;39(6):356-61. doi: 10.1016/j.aller.2010.12.007
41. Saleem K, Azim W. Association of vitiligo with other autoimmune disorders. Diabetes Case Rep. 2016;1(3). doi: 10.4172/2572-5629.1000114
42. Sedighe M, Gholamhossein G. Thyroid dysfunction and thyroid antibodies in Iranian patiens with vitiligo. Indian J Dermatol. 2008;53(1):9-11. doi: 10.4103/0019-5154.39733
43. Sivasubramanian A, Ganapathi S. The study on association of co-morbidities in female patients with vitiligo. Int J Res Dermatol. 2019;5(1):203. doi: 10.18203/issn.2455-4529
44. Tanioka M, Yamamoto Y, Katoh M, et al. Vitiligo vulgaris and autoimmune diseases in Japan: a report from vitiligo clinic in Kyoto University Hospital. Dermatoendocrinol. 2009;1(1):43-5. doi: 10.4161/derm.1.1.7306
45. Topal OI, Duman H, Gungor S, et al. Evaluation of the clinical and sociodemographic features of Turkish patients with vitiligo. Acta Dermatovenerol Croat. 2016;24(2):124-9. https://hrcak.srce.hr/161242
46. Vachiramon V, Harnchoowong S, Onprasert W, Chanprapaph K. Prevalence of thyroid abnormalities in thai patients with vitiligo. Biomed Res Int. 2017;2017:1-6. doi: 10.1155/2017/7502935
47. Yang Y, Huang G, Yan X, Qing Z. Clinical analysis of thyroglobulin antibody and thyroid peroxidase antibody and their association with vitiligo. Indian J Dermatol. 2014;59(4):357. doi: 10.4103/0019-5154.135485
48. Zhang Z, Xu S, Zhang F, et al. The analysis of genetics and associated autoimmune diseases in Chinese vitiligo patients. Arch Dermatol Res. 2009;301(2):167-73. doi: 10.1007/s00403-008-0900-z
49. Iacovelli P, Sinagra J, Vidolin A, et al. Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology. 2005;210(1):26-30. doi: 10.1159/000081479
50. Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, et al. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol. 2005;53(2):220-3. doi: 10.1016/j.jaad.2005.03.032
51. Kroon M, Vrijman C, Chandeck C, et al. High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr.2013;79(3):137-44. doi: 10.1159/000348388
52. Mazereeuw-Hautier J, Bezio S, Mahe E, et al. Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: A prospective observational study. J Am Acad Dermatol. 2010;62(6):945-9. doi: 10.1016/j.jaad.2009.06.081
53. Prćić S, Djuran V, Katanić D, et al. Vitiligo and thyroid dysfunction in children and adolescents. Acta Dermatovenerol Croat. 2011;19(4):248-54.
54. Cho S, Kim J, Cho S, et al. Vitiligo in children and adolescents: association with thyroid dysfunction. J Eur Acad Dermatol Venereol. 2011;25(1):64-7. doi: 10.1111/j.1468-3083.2010.03694.x
55. Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from North India. Pediatr Dermatol. 2003;20(3):207-10. doi: 10.1046/j.1525-1470.2003.20304.x
56. Uncu S, Yaylı S, Bahadır S, et al. Relevance of autoimmune thyroiditis in children and adolescents with vitiligo. Int J Dermatol. 2011;50(2):175-9. doi: 10.1111/j.1365-4632.2010.04665.x
57. Yang Y, Lin X, Fu W, et al. An approach to the correlation between vitiligo and autoimmune thyroiditis in Chinese children. Clin Exp Dermatol. 2010;35(7):706-10. doi: 10.1111/j.1365-2230.2009.03671.x
58. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010 Feb;123(2):183.e1-9. doi: 10.1016/j.amjmed.2009.06.030
59. Ruggeri R, Trimarchi F, Giuffrida G, et al. Autoimmune comorbidities in Hashimoto’s thyroiditis: different patterns of association in adulthood and childhood/adolescence. Eur J Endocrinol. 2017;176(2):133-41. doi: 10.1530/EJE-16-0737
60. Prindaville B, Rivkees S. Incidence of vitiligo in children with Graves' disease and Hashimoto's thyroiditis. Int J Pediatr Endocrinol. 2011;2011(1):18. doi: 10.1186/1687-9856-2011-18
61. Gong Q, Li X, Gong Q, et al. Hashimoto’s thyroiditis could be secondary to vitiligo: the possibility of antigen crossover and oxidative stress between the two diseases. Arch Dermatol Res. 2016;308(4):277-81. doi: 10.1007/s00403-016-1641-z
62. Slominski A, Pisarchik A, Wortsman J, et al. Expression of hypothalamic–pituitary–thyroid axis related genes in the human skin. J Invest Dermatol. 2002;119(6):1449-55. doi: 10.1046/j.1523-1747.2002.19617.x
63. Cianfarani F, Baldini E, Cavalli A, et al. TSH receptor and thyroid-specific gene expression in human skin. J Invest Dermatol. 2010;130(1):93-101. doi: 10.1038/jid.2009.180
64. Ferrari S, Fallahi P, Ruffilli I, et al. The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series. Autoimmun Rev. 2019;18(3):287-92. doi: 10.1016/j.autrev.2018.10.001
65. Liu CW, Huang YC. Vitiligo and autoantibodies: a systematic review and meta-analysis. J Dtsch Dermatol Ges. 2018;16(7):845-51. doi: 10.1111/ddg.13574
66. Lim HK, Bae MI, Jeong KH, et al. Positivity rates of antithyroid antibody, antinuclear antibody and thyroid peroxidase antibody in different types of vitiligo. Clin Exp Dermatol. 2016;41(3):242-7. doi: 10.1111/ced.12771
67. Onunu A, Kubeyinje E. Vitiligo in the Nigerian African: a study of 351 patients in Benin City, Nigeria. Int J Dermatol. 2003;42(10):800-2. doi: 10.1046/j.1365-4362.2003.01908.x
68. Nederstigt C, Uitbeijerse B, Janssen L, et al. Associated autoimmune disease in type 1 diabetes patients: a systematic review and meta-analysis. Eur J Endocrinol. 2019;180(2):135-44. doi: 10.1530/EJE-18-0515
69. Afkhami-Ardekani M, Ghadiri-Anari A, Ebrahimzadeh-Ardakani M, Zaji N. Prevalence of vitiligo among type 2 diabetic patients in an Iranian population. Int J Dermatol. 2014;53(8):956-8. doi: 10.1111/ijd.12148
70. Chang HC, Lin MH, Huang YC, Hou TY. The association between vitiligo and diabetes mellitus: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;81(6):1442-5. doi: 10.1016/j.jaad.2019.06.022
71. Farhan J, Al-Shobaili H, Zafar U, et al. Interleukin-6: a possible inflammatory link between vitiligo and type 1 diabetes. Br J Biomed Sci. 2014;71(4):151-7. doi: 10.1080/09674845.2014.11669980
72. Meyer G, Neumann K, Badenhoop K, Linder R. Increasing prevalence of Addison's disease in German females: health insurance data 2008–2012. Eur J Endocrinol. 2014;170(3):367-73. doi: 10.1530/EJE-13-0756
73. Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome Type 2: the tip of an iceberg? Clin Exp Immunol. 2004;137(2):225-33. doi: 10.1111/j.1365-2249.2004.02561.x
74. Amerio P, Tracanna M, De Remigis P, et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B + C and 4. Clin Exp Dermatol. 2006;31(5):746-9. doi: 10.1111/j.1365-2230.2006.02171.x
75. Amerio P, Di Rollo D, Carbone A, et al. Polyglandular autoimmune diseases in a dermatological clinical setting: vitiligo-associated autoimmune diseases. Eur J Dermatol. 2010;20(3):354-8. doi: 10.1684/ejd.2009.0939
76. Dittmar M, Kahaly G. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab. 2003;88(7):2983-92. doi: 10.1210/jc.2002-021845
77. Perheentupa J. Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. J Clin Endocrinol Metab. 2006;91(8):2843-50. doi: 10.1210/jc.2005-2611
78. Ferre E, Rose S, Rosenzweig S, et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight. 2016;1(13):e88782. doi: 10.1172/jci.insight.88782
79. Bruserud Ø, Oftedal B, Landegren N, et al. A Longitudinal follow-up of Autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2016;101(8):2975-83. doi: 10.1210/jc.2016-1821
80. Turiev GS. Autoimmune diseases in diabetes mellitus in adult patients. Vladikavkazskij mediko-biologich. vestn. 2013;17(26):74-80 (In Russ.)
81. Orlova EM, Sozaeva LS, Kareva MA, et al. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2017;102(9):3546-56. doi: 10.1210/jc.2017-00139
82. Lomonosov KM, Simonova NI, Lomonosov MK. Comparative analysis of serum autoantibodies in patients with vitiligo. Ros. zhurn. kozhnyh i venericheskih boleznej. 2013;2:35 (In Russ.)
Авторы
________________________________________________
1 Endocrinology Research Centre, Moscow, Russia;
2 Moscow Research and Practical Center for Dermatovenereology and Cosmetology, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.